aTyr Pharma Inc  

(Public, NASDAQ:LIFE)   Watch this stock  
Find more results for LIFE
+0.15 (4.41%)
After Hours: 3.55 0.00 (0.00%)
May 22, 5:46PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.35 - 3.60
52 week 2.10 - 4.45
Open 3.40
Vol / Avg. 0.00/35,323.00
Mkt cap 86.42M
P/E     -
Div/yield     -
EPS -2.33
Shares 23.81M
Beta     -
Inst. own 77%
Aug 8, 2017
Q2 2017 aTyr Pharma Inc Earnings Release (Estimated) Add to calendar
May 11, 2017
Q1 2017 aTyr Pharma Inc Earnings Release
Apr 4, 2017
aTyr Pharma Inc at Needham Healthcare Conference
Mar 16, 2017
Q4 2016 aTyr Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -73.52% -55.05%
Return on average equity -94.74% -65.06%
Employees 58 -
CDP Score - -


3545 John Hopkins Ct Ste 250
SAN DIEGO, CA 92121-1115
United States - Map
+1-858-7318389 (Phone)
+1-858-7318394 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Officers and directors

John D. Mendlein Ph.D. Chief Executive Officer and Executive Chairman, Board of Directors
Age: 56
Bio & Compensation  - Reuters
John T. Blake Principal Financial Officer, Chief Accounting Officer
Age: 39
Bio & Compensation  - Reuters
David John King Ph.D. Senior Vice President - Research
Bio & Compensation  - Reuters
Melissa A Ashlock Vice President - External Scientific Alliances and Human Genetics
Age: 57
Bio & Compensation  - Reuters
Holly D Chrzanowski Vice President - Enterprise Talent and Organization
Age: 49
Bio & Compensation  - Reuters
Andrew Cubitt Vice President - Product Protection
Age: 52
Bio & Compensation  - Reuters
John C McKew Vice President - Research
Age: 51
Bio & Compensation  - Reuters
Fred Ramsdell Vice President - Immunology
Age: 54
Bio & Compensation  - Reuters
Sanuj K Ravindran M.D. Chief Business Officer
Bio & Compensation  - Reuters
Sanjay S Shukla M.D. Chief Medical Officer
Bio & Compensation  - Reuters